Phase 2 Adaptive ADT and Docetaxel Trial for mCSPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Recruiting: WOMBAT Study on Bipolar Androgen Therapy for Prostate Cancer
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxNewsletter 1/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week I took a little time to soak up the holiday season, and I’m guessing the researchers did too! This week didn’t bring much in the way of breaking news, but let’s face it—there’s never a week without some fresh study popping up […]
Phase 1 Clinical Trial: The PHAROS Trial Investigates Novel ACK1 Inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTags
abiraterone acetate ADC ADT androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody cancer cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology PARP inhibitor PEACE-1 personalized medicine prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery theranostics tumor microenvironment
Latest Posts
- Newsletter 3/2025 January 19, 2025
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025